Intarcia Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Intarcia Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C0486
◆発行会社(調査会社):GlobalData
◆発行日:2018年7月
◆ページ数:35
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Intarcia Therapeutics Inc (Intarcia), formerly BioMedicines Inc is a biopharmaceutical company that discovers, develops and commercializes drug therapies. The company’s product candidates include ITCA 650, used for the treatment of type II diabetes and obesity. It offers technology platform that helps to develop proprietary formulations and evaluation of drug candidates through formulations. Intarcia uses Medici drug delivery system, a subcutaneous delivery system to maintain the optimal level of highly potent small molecules in the human body such as proteins, antibody fragments and peptides. The company operates manufacturing facility in Hayward. Intarcia is headquartered in Boston, Massachusetts, the US.

Intarcia Therapeutics Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Intarcia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Intarcia Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Intarcia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Intarcia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Intarcia Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 9
Intarcia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Intarcia Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Intarcia Therapeutics Raises USD75 Million in Financing 12
Phoundry Pharma Raises USD0.5 Million in Seed Financing 13
Intarcia Therapeutics Raises US$200 Million In Venture Financing 14
Intarcia Therapeutics Raises US$210 Million In Venture Financing 16
Intarcia Therapeutics Raises USD0.7 Million in Venture Financing 18
Intarcia Therapeutics Raises Additional US$5.5 Million In Venture financing 19
Intarcia Therapeutics Raises US$7.3 Million In Venture financing 20
Partnerships 22
Intarcia Therapeutics Enters into Co-Development Agreement with Numab 22
Intarcia Therapeutics Enters into Co-Development Agreement with Servier for ITCA 650 23
Licensing Agreements 24
Intarcia Therapeutics Enters into Licensing Agreement with California Institute for Biomedical Research 24
Intarcia Therapeutics Plans To License Drug-Formulation Technology 25
Equity Offering 26
Intarcia Therapeutics Raises USD206 Million in Second Tranche of Private Placement of Shares 26
Intarcia Therapeutics Raises USD215 Million in First Tranche of Private Placement of Shares 27
Debt Offering 28
Intarcia Therapeutics Raises USD300 Million in Financing 28
Acquisition 29
Intarcia Therapeutics Acquires Phoundry Pharma 29
Intarcia Therapeutics Inc – Key Competitors 30
Intarcia Therapeutics Inc – Key Employees 31
Intarcia Therapeutics Inc – Locations And Subsidiaries 32
Head Office 32
Other Locations & Subsidiaries 32
Recent Developments 33
Product News 33
09/15/2017: New Intarcia Study Evaluates Optimal Way to Switch from Daily Liraglutide Injections to ITCA 650 in Patients with Type 2 Diabetes 33
Product Approvals 34
Feb 03, 2017: Intarcia Announces FDA Filing Acceptance of New Drug Application (NDA) for ITCA 650 for the Treatment of Type 2 Diabetes 34
Appendix 35
Methodology 35
About GlobalData 35
Contact Us 35
Disclaimer 35

List of Tables
Intarcia Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts 2
Intarcia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Intarcia Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Intarcia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Intarcia Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Intarcia Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 9
Intarcia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Intarcia Therapeutics Raises USD75 Million in Financing 12
Phoundry Pharma Raises USD0.5 Million in Seed Financing 13
Intarcia Therapeutics Raises US$200 Million In Venture Financing 14
Intarcia Therapeutics Raises US$210 Million In Venture Financing 16
Intarcia Therapeutics Raises USD0.7 Million in Venture Financing 18
Intarcia Therapeutics Raises Additional US$5.5 Million In Venture financing 19
Intarcia Therapeutics Raises US$7.3 Million In Venture financing 20
Intarcia Therapeutics Enters into Co-Development Agreement with Numab 22
Intarcia Therapeutics Enters into Co-Development Agreement with Servier for ITCA 650 23
Intarcia Therapeutics Enters into Licensing Agreement with California Institute for Biomedical Research 24
Intarcia Therapeutics Plans To License Drug-Formulation Technology 25
Intarcia Therapeutics Raises USD206 Million in Second Tranche of Private Placement of Shares 26
Intarcia Therapeutics Raises USD215 Million in First Tranche of Private Placement of Shares 27
Intarcia Therapeutics Raises USD300 Million in Financing 28
Intarcia Therapeutics Acquires Phoundry Pharma 29
Intarcia Therapeutics Inc, Key Competitors 30
Intarcia Therapeutics Inc, Key Employees 31
Intarcia Therapeutics Inc, Other Locations 32
Intarcia Therapeutics Inc, Subsidiaries 32

List of Figures
Intarcia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Intarcia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Intarcia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Intarcia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Intarcia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Intarcia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Intarcia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Intarcia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Intarcia Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Intarcia Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Chicago Bridge & Iron Company N.V.:企業の戦略・SWOT・財務情報
    Chicago Bridge & Iron Company N.V. - Strategy, SWOT and Corporate Finance Report Summary Chicago Bridge & Iron Company N.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • TBC Insurance JSC:企業の戦略的SWOT分析
    TBC Insurance JSC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Bank Albilad:企業の戦略・SWOT・財務分析
    Bank Albilad - Strategy, SWOT and Corporate Finance Report Summary Bank Albilad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Premier Biomedical Inc (BIEI):製薬・医療:M&Aディール及び事業提携情報
    Summary Premier Biomedical Inc (Premier Biomedical) is a drug development company that develops medications for debilitating and fatal illnesses. The company offers Feldetrex, a drug candidate used for the treatment of multiple sclerosis, fibromyalgia, blood sepsis and viremia, and cancer. It develo …
  • Welch Allyn Inc:医療機器:M&Aディール及び事業提携情報
    Summary Welch Allyn Inc (Welch Allyn) manufactures and markets a comprehensive range of products for physical assessment, vital signs monitoring, diagnostic cardiopulmonary, software and services, and thermometry. It also offers parts and accessories including miscellaneous parts, BP cuffs, cables a …
  • algoWatt SpA (ALW):企業の財務・戦略的SWOT分析
    Summary algoWatt SpA (algoWatt), formerly TerniEnergia SpA, is an energy services provider. It designs, develops and integrates solutions for the management of energy and natural resources. The company’s product offerings include building energy management systems, control and maintenance systems, e …
  • PENTAX Medical Co:医療機器:M&Aディール及び事業提携情報
    Summary Pentax Medical Co (Pentax Medical), a subsidiary of Pentax of America Inc, is a medical device company that offers endoscopic products and services. The company offers products such as colonoscopes, sigmoidscopes, echoendoscopes, small bowel enteroscope, duodenoscopes, choledochoscope, advan …
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development:製薬・医療:M&Aディール及び事業提携情報
    Summary Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), a subsidiary of National Institutes of Health, is a research institute that conducts and supports laboratory research, clinical trials, and epidemiological studies. The institute conducts research in the …
  • Southern California Edison Co:電力:M&Aディール及び事業提携情報
    Summary Southern California Edison Co (SCE), a subsidiary of Edison International, is an electric utility that generates, procures, sources, and supplies electricity. The company generates electricity from various sources including natural gas, hydro, nuclear, solar, and oil and gas. It sources rema …
  • Zoll Medical Corp:企業の戦略的SWOT分析
    Zoll Medical Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Investors Heritage Capital Corporation:企業の戦略・SWOT・財務情報
    Investors Heritage Capital Corporation - Strategy, SWOT and Corporate Finance Report Summary Investors Heritage Capital Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT ana …
  • The Quizno’s Master LLC:企業の戦略・SWOT・財務情報
    The Quizno’s Master LLC - Strategy, SWOT and Corporate Finance Report Summary The Quizno’s Master LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Islet Sciences Inc (ISLT):企業の財務・戦略的SWOT分析
    Summary Islet Sciences Inc (Islet Sciences) is a drug development company that develops medicines and technologies for the treatment of metabolic diseases. The company's pipeline products include immune modulating small molecule interleukin 12 inhibitors to address disorders associated with inflamma …
  • Perenco Holdings:石油・ガス:M&Aディール及び事業提携情報
    Summary Perenco Holdings (Perenco) is an independent upstream energy company. It explores for, develops, produces, transports, and stores oil and gas. The company’s oil fields ranges from Northern Europe to Africa and Latin America to Southeast Asia. Through spot sales and long term sales agreements …
  • Fauji Fertilizer Bin Qasim Limited (FFBL)-エネルギー分野:企業M&A・提携分析
    Summary Fauji Fertilizer Bin Qasim Limited (FFBL) is a chemical manufacturing company that manufactures, supplies and markets di ammonium phosphate (DAP) and granular urea. In addition, the company undertakes production and marketing of ammonia and other nitrogenous fertilizers for agricultural appl …
  • Capsugel Inc:企業の戦略的SWOT分析
    Capsugel Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Hoteis Othon SA:企業の戦略・SWOT・財務情報
    Hoteis Othon SA - Strategy, SWOT and Corporate Finance Report Summary Hoteis Othon SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Teva Pharmaceutical Industries Ltd (TEVA)-製薬・医療分野:企業M&A・提携分析
    Summary Teva Pharmaceutical Industries Ltd (Teva) carries out the research, development, manufacture and commercialization of generic and specialty medicines. It provides specialty medicines in central nervous system (CNS), respiratory, cancer, women’s health and other therapy areas. The company off …
  • MYnd Analytics Inc (MYND):医療機器:M&Aディール及び事業提携情報
    Summary MYnd Analytics Inc (MYnd Analytics), formerly CNS Response Inc, is a predictive analytics company. The company develops a decision support tool that assists physicians in the provision of personalized medication for individual patients suffering from mental health issues. It provides Psychia …
  • Eupraxia Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Eupraxia Pharmaceuticals Inc (Eupraxia Pharma) is a drug development company that offers pain management solutions. The company’s technology encapsulates pharmaceutical micro particles in a polymer shell which helps to extend drug release from days to months. Its pipeline products include EP …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆